Zacks Research Issues Negative Forecast for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Esperion Therapeutics in a report issued on Tuesday, February 3rd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, down from their previous forecast of $0.04. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2027 earnings at $0.01 EPS and FY2027 earnings at $0.26 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The company had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million.

Several other research firms also recently weighed in on ESPR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.20.

Esperion Therapeutics Trading Down 2.6%

Shares of NASDAQ ESPR opened at $3.42 on Wednesday. The stock has a fifty day simple moving average of $3.64 and a two-hundred day simple moving average of $2.88. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $4.18. The firm has a market cap of $817.59 million, a price-to-earnings ratio of -6.84, a price-to-earnings-growth ratio of 7.17 and a beta of 1.09.

Institutional Trading of Esperion Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd lifted its position in Esperion Therapeutics by 23.5% in the 4th quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 2,890 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Esperion Therapeutics by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 3,614 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 3,822 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Esperion Therapeutics by 18.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 4,422 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Esperion Therapeutics by 7.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 4,979 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Esperion Therapeutics

In other news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the completion of the transaction, the chief financial officer directly owned 467,525 shares in the company, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 15,543 shares of company stock valued at $55,709 in the last three months. 1.70% of the stock is currently owned by company insiders.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.